Anna Pagonakis

Array ( [id] => 9046848 [patent_doc_number] => 08541403 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-09-24 [patent_title] => 'Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency' [patent_app_type] => utility [patent_app_number] => 13/020619 [patent_app_country] => US [patent_app_date] => 2011-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 42952 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13020619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7791630 [patent_doc_number] => 20120053186 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-03-01 [patent_title] => '2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS' [patent_app_type] => utility [patent_app_number] => 13/015664 [patent_app_country] => US [patent_app_date] => 2011-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 21581 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0053/20120053186.pdf [firstpage_image] =>[orig_patent_app_number] => 13015664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8659099 [patent_doc_number] => 20130039928 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-02-14 [patent_title] => 'COMPOSITIONS AND METHODS FOR REVERSING CORTICOSTEROID RESISTANCE OR TREATING RESPIRATORY INFECTIONS' [patent_app_type] => utility [patent_app_number] => 13/575880 [patent_app_country] => US [patent_app_date] => 2011-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 26631 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13575880 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8313693 [patent_doc_number] => 20120190715 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-26 [patent_title] => 'HIGHLY PENETRATING COMPOSITIONS AND METHODS FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES' [patent_app_type] => utility [patent_app_number] => 13/012719 [patent_app_country] => US [patent_app_date] => 2011-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 18603 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13012719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6110274 [patent_doc_number] => 20110189174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-08-04 [patent_title] => 'COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR INHIBITING PROGRESSION OF, PATHOGENIC OCULAR NEOVASCULARIZATION' [patent_app_type] => utility [patent_app_number] => 13/009894 [patent_app_country] => US [patent_app_date] => 2011-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 29207 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0189/20110189174.pdf [firstpage_image] =>[orig_patent_app_number] => 13009894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6178183 [patent_doc_number] => 20110178171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-21 [patent_title] => 'COMPOUNDS FOR CANCER THERAPY' [patent_app_type] => utility [patent_app_number] => 13/008597 [patent_app_country] => US [patent_app_date] => 2011-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 12345 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0178/20110178171.pdf [firstpage_image] =>[orig_patent_app_number] => 13008597 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6062238 [patent_doc_number] => 20110200619 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-08-18 [patent_title] => 'PHARMACEUTICAL COMPOUNDS AS CYTOTOXIC AGENTS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/004311 [patent_app_country] => US [patent_app_date] => 2011-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6743 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0200/20110200619.pdf [firstpage_image] =>[orig_patent_app_number] => 13004311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8490110 [patent_doc_number] => 20120289517 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-15 [patent_title] => 'SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION' [patent_app_type] => utility [patent_app_number] => 13/519333 [patent_app_country] => US [patent_app_date] => 2010-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 3091 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13519333 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8649614 [patent_doc_number] => 20130035344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-02-07 [patent_title] => 'PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION' [patent_app_type] => utility [patent_app_number] => 13/519905 [patent_app_country] => US [patent_app_date] => 2010-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 5367 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13519905 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6213968 [patent_doc_number] => 20110136774 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-09 [patent_title] => 'Anti-Apoptotic Benzodiazepine Receptor Ligand Inhibitors' [patent_app_type] => utility [patent_app_number] => 12/974913 [patent_app_country] => US [patent_app_date] => 2010-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 20172 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 36 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0136/20110136774.pdf [firstpage_image] =>[orig_patent_app_number] => 12974913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6128007 [patent_doc_number] => 20110086868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-04-14 [patent_title] => 'SPECIFIC INHIBITORS FOR VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS' [patent_app_type] => utility [patent_app_number] => 12/969848 [patent_app_country] => US [patent_app_date] => 2010-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8802 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0086/20110086868.pdf [firstpage_image] =>[orig_patent_app_number] => 12969848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8523407 [patent_doc_number] => 20120322815 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-20 [patent_title] => 'PHARMACEUTICAL COMPOSITION CONTAINING A3 ADENOSINE RECEPTOR AGONIST' [patent_app_type] => utility [patent_app_number] => 13/516634 [patent_app_country] => US [patent_app_date] => 2010-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 12275 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13516634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9977550 [patent_doc_number] => 09023861 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-05-05 [patent_title] => 'Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents' [patent_app_type] => utility [patent_app_number] => 13/518185 [patent_app_country] => US [patent_app_date] => 2010-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6480 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13518185 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8221761 [patent_doc_number] => 20120135970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-31 [patent_title] => 'COMPOSITIONS FOR PREVENTING AND TREATING AN IMMUNE SYSTEM DISORDER' [patent_app_type] => utility [patent_app_number] => 12/955551 [patent_app_country] => US [patent_app_date] => 2010-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 5470 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12955551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6163296 [patent_doc_number] => 20110160236 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-30 [patent_title] => 'Treating Vascular Events with Statins by Inhibiting PAR-1 and PAR-4' [patent_app_type] => utility [patent_app_number] => 12/955900 [patent_app_country] => US [patent_app_date] => 2010-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8996 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0160/20110160236.pdf [firstpage_image] =>[orig_patent_app_number] => 12955900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6142342 [patent_doc_number] => 20110129550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-02 [patent_title] => 'CANCER TREATMENT METHOD' [patent_app_type] => utility [patent_app_number] => 12/948159 [patent_app_country] => US [patent_app_date] => 2010-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 14666 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0129/20110129550.pdf [firstpage_image] =>[orig_patent_app_number] => 12948159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7511554 [patent_doc_number] => 20110257264 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-10-20 [patent_title] => 'USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS' [patent_app_type] => utility [patent_app_number] => 12/946742 [patent_app_country] => US [patent_app_date] => 2010-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 15086 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0257/20110257264.pdf [firstpage_image] =>[orig_patent_app_number] => 12946742 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9355380 [patent_doc_number] => 08673913 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-03-18 [patent_title] => 'SHP-2 phosphatase inhibitor' [patent_app_type] => utility [patent_app_number] => 12/946480 [patent_app_country] => US [patent_app_date] => 2010-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 23 [patent_no_of_words] => 13927 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12946480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5972752 [patent_doc_number] => 20110152267 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-23 [patent_title] => 'Compositions and Methods for Treating Hyperproliferative Disorders' [patent_app_type] => utility [patent_app_number] => 12/945808 [patent_app_country] => US [patent_app_date] => 2010-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 15601 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0152/20110152267.pdf [firstpage_image] =>[orig_patent_app_number] => 12945808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8465704 [patent_doc_number] => 20120270871 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-25 [patent_title] => 'PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES' [patent_app_type] => utility [patent_app_number] => 13/518726 [patent_app_country] => US [patent_app_date] => 2010-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21030 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13518726 [rel_patent_id] =>[rel_patent_doc_number] =>)